Chardan analyst Andreas Argyrides raised the firm's price target on EyePoint to $65 from $29 and keeps a Buy rating on the shares as coverage was transferred. The firm, which believes that EyePoint is "a de-risked, single-asset, catalyst-rich story" heading into pivotal readouts from Phase 3 studies of DURAVYU in wet AMD expected in August and October this year, says the two largest retinal markets - wet AMD and DME - together represent about $13B in U.S. sales next year.
